Promising combo tackles tough liver cancer in small trial
NCT ID NCT04301778
First seen Mar 15, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study tested a combination of two drugs (durvalumab and SNDX-6352) in 5 adults with a type of liver cancer that cannot be surgically removed. The goal was to see if the combo could shrink tumors or slow the cancer after standard liver-directed treatments. The trial focused on safety and how well the drugs worked together.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.